News & Updates
Faces of Lung Cancer Report
Reflection of COVID-19. The annual report is now available!
Bristol-Myers Squibb Canada Co. (BMS Canada) today announced that Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care have agreed to cover the cost of the immuno-oncology treatment OPDIVO® for three different difficult-to-treat tumour types, effective March 20, 2017.
Major Step Forward in Accessing New Life-Extending Medication for Advanced Metastatic Lung, Melanoma and Kidney Cancer Patients.
Canadian lung, melanoma and kidney cancer patients are one step closer to gaining access to immunotherapy after pCPA negotiations have concluded. Provinces and Territories are encouraged to list quickly.
Cancer Care Ontario is introducing a lung cancer screening pilot program for people at high risk in April 2017.
New Research Shows Canadian Lung Cancer Patients Are Disadvantaged Compared to Their US Peers and Shocking Trends Among Women
The Canadian Cancer Society has released the Canadian Cancer Statistics 2016. Lung cancer remains deadliest cancer for CDN men & women the lowest 5-year survival (17%) of any major cancer.
Thank you to everyone who participated in the Scotiabank Toronto Waterfront Marathon in support of lung cancer!
As a healthy, active non-smoker, Jessica Steinberg was shocked by her diagnosis. Jessica had to face a life-threatening cancer diagnosis while juggling single parenthood.
pCODR recommends nivolumab (Opdivo) for funding in its Final Recommendation for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required.
This is a great news for NSCLC patients! We hope to see more like this for other types of lung cancer.
Lung Cancer Canada has added two new social media profiles.
Follow us on LinkedIn and Instagram!